Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB

By LabMedica International staff writers
Posted on 11 Apr 2022

Gentian Diagnostics (Moss, Norway) exhibited its range of assays for highly relevant biomarkers for a wide range of clinical chemistry platforms at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EUROMEDLAB) in Munich, Germany. More...

Gentian demonstrated its Calprotectin Immunoassay (GCAL) assay, which is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation. Calprotectin in plasma and serum is a sensitive and early biomarker in detection of inflammation and inflammatory response in infections. Calprotectin has been reported as diagnostic marker in the discrimination between bacterial and viral infection, in assessment of severe infections and sepsis and in the prediction for development of severe infections. Interestingly, calprotectin has also been reported a risk marker in severe COVID-19, which in contrast to other viral infection induces a hyperinflammation response and pathways mimic bacterial sepsis. Gentian’s GCAL is an open channel assay, meaning it can be added to all clinical chemistry analyzers.

Gentian also promoted its turbidimetric Cystatin C Immunoassay which is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function1 for patients of all ages. The Cystatin C Immunoassay has documented high inter-instrument accuracy on a wide range of clinical chemistry analyzers. Gentian also promoted its new turbidimetric SARS-CoV-2 Total Antibody Immunoassay which is a quantitative antibody test that captures the full immune response detecting antibodies targeting the S1-subunit with high sensitivity and specificity. It will be calibrated against the international WHO international standard. Since the Gentian assay is platform agnostic, it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test follows a standard testing protocol utilizing existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.

Related Links:
Gentian Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automatic CLIA Analyzer
Shine i6000
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.